The Goldman Sachs Group Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price target cut by research analysts at The Goldman Sachs Group from $326.00 to $277.00 in a research report issued on Wednesday, MarketBeat.com reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s price target points to a potential upside of 38.90% from the company’s previous close.

PODD has been the subject of several other reports. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Zacks Research cut Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target for the company. in a report on Monday, January 26th. Evercore dropped their price target on Insulet from $340.00 to $240.00 and set an “outperform” rating for the company in a report on Monday. Finally, Citigroup cut Insulet from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $338.00 to $230.00 in a report on Tuesday. Nineteen equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $342.00.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $199.42 on Wednesday. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. Insulet has a 12 month low of $197.54 and a 12 month high of $354.88. The stock has a 50 day moving average of $233.42 and a 200-day moving average of $280.87. The company has a market capitalization of $13.81 billion, a P/E ratio of 56.98, a P/E/G ratio of 1.22 and a beta of 1.47.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. The business had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the firm posted $1.15 EPS. As a group, equities research analysts predict that Insulet will post 3.92 EPS for the current year.

Insiders Place Their Bets

In related news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. Larson Financial Group LLC raised its holdings in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in Insulet in the 4th quarter valued at $28,000. DV Equities LLC acquired a new position in Insulet in the 4th quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new position in Insulet in the 4th quarter valued at $29,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several analysts published bullish upside estimates pointing to long-term growth potential in Insulet’s tubeless insulin-pump business, highlighting significant upside from current levels — this supports a constructive thesis for patient investors. Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum
• Positive Sentiment: Goldman Sachs trimmed its price target from $326 to $277 but kept a “Buy” rating — this reduces implied upside versus prior targets but signals continued confidence in Insulet’s growth trajectory. Goldman Sachs adjusts price target on Insulet to $277 from $326; maintains Buy
• Neutral Sentiment: Several boutiques and media lists include PODD among multi-year “high-upside” or “explosive” stock picks — useful for sentiment but less material short term unless backed by new fundamentals. 5 Stocks Set to Explode in the Next 3 Years (InsiderMonkey)
• Neutral Sentiment: Analysts’ consensus still sits around a “Moderate Buy,” showing broad support among analysts even as individual targets shift — this tempers panic selling but may limit immediate upside. Insulet Receives Consensus Recommendation of “Moderate Buy”
• Negative Sentiment: Citigroup downgraded Insulet to Neutral, signaling reduced conviction and likely contributing to near-term selling pressure and the stock hitting a 12‑month low. Citigroup Downgrades Insulet (NASDAQ:PODD) to Neutral
• Negative Sentiment: Evercore cut its price target to $240, trimming the near‑term valuation runway and adding to analyst-driven downside momentum. Evercore Cuts Insulet Price Target to $240
• Negative Sentiment: Coverage and headlines noting that the stock hit a new 12‑month low emphasize the current negative technical/momentum backdrop, which can amplify outflows. Insulet Hits New 12-Month Low on Analyst Downgrade
• Negative Sentiment: Pomerantz LLP has opened an investor investigation into Insulet, introducing potential legal/financial risk that could weigh on sentiment and attract regulatory scrutiny. Legal inquiries tend to increase uncertainty and can pressure the stock until resolved. Pomerantz Law Firm Investigates Claims On Behalf of Insulet Investors

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.